Wordt geladen...
PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
Programmed cell death protein 1 receptor and programmed cell death ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) that provide a survival benefit for select patients with advanced non–small cell lung cancer (NSCLC). Nivolumab, pembrolizumab, and atezolizumab are second-line ther...
Bewaard in:
| Gepubliceerd in: | J Adv Pract Oncol |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Harborside Press LLC
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7522661/ https://ncbi.nlm.nih.gov/pubmed/33014515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2019.10.2.11 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|